HIV drug resistance in low-income and middle-income countries

RL Hamers, TFR de Wit, CB Holmes - The Lancet HIV, 2018 - thelancet.com
After 15 years of global scale-up of antiretroviral therapy (ART), rising prevalence of HIV
drug resistance in many low-income and middle-income countries (LMICs) poses a growing …

Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era

SM McCluskey, T Pepperrell, A Hill, WDF Venter… - Aids, 2021 - journals.lww.com
Dolutegravir (DTG) is now a component of preferred first-line antiretroviral therapy (ART)
worldwide. ADVANCE and NAMSAL were two landmark clinical trials conducted exclusively …

Dolutegravir-based or low-dose efavirenz–based regimen for the treatment of HIV-1

NAMSAL ANRS 12313 Study … - New England Journal of …, 2019 - Mass Medical Soc
Background An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as
EFV600) was the World Health Organization preferred first-line treatment for human …

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase

MJ Siedner, MA Moorhouse, B Simmons… - Nature …, 2020 - nature.com
Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of
second generation integrase inhibitors. We sequenced pretreatment plasma specimens …

Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens

SC Inzaule, RL Hamers, M Doherty… - The Lancet Infectious …, 2019 - thelancet.com
To improve virological suppression and address the emerging threat of HIV drug resistance,
many low-income and middle-income countries are moving away from non-nucleoside …

Epidemiology of HIV drug resistance in low-and middle-income countries and WHO global strategy to monitor its emergence

S Bertagnolio, MR Jordan, A Giron… - Current Opinion in HIV …, 2022 - journals.lww.com
Epidemiology of HIV drug resistance in low- and middle-incom... : Current Opinion in HIV and
AIDS Epidemiology of HIV drug resistance in low- and middle-income countries and WHO …

Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naive individuals: a systematic review of detection methods, prevalence, and clinical impact

HA Mbunkah, S Bertagnolio, RL Hamers… - The Journal of …, 2020 - academic.oup.com
Background The presence of high-abundance drug-resistant HIV-1 jeopardizes success of
antiretroviral therapy (ART). Despite numerous investigations, the clinical impact of low …

High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam

GM Bwire, BG Aiko, IH Mosha, MS Kilapilo… - Scientific Reports, 2023 - nature.com
To curb HIV infection rate in Tanzania, antiretroviral therapy (ART) has been scaled up since
2006, and in 2019, the country shifted to regimen including dolutegravir as a default first line …

High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage …

K Huik, S Hill, J George, A Pau, S Kuriakose… - AIDS, 2022 - journals.lww.com
The integrase strand transfer inhibitor (INSTI) dolutegravir is commonly used in combination
antiretroviral therapy regimens and retains strong potency even with primary resistance …

Pre-treatment integrase inhibitor resistance and natural polymorphisms among HIV-1 subtype C infected patients in Ethiopia

DA Arimide, ZI Szojka, K Zealiyas, A Gebreegziabxier… - Viruses, 2022 - mdpi.com
Dolutegravir-based antiretroviral therapy (ART) has been scaled up in many developing
countries, including Ethiopia. However, subtype-dependent polymorphic differences might …